About
Biotech Brief
The 5-minute daily briefing for biotech investors, operators, and BD teams who need to know what happened, why it matters, and what to watch next — before the market opens.
What we cover
Every weekday, Biotech Brief monitors sources across clinical readouts, FDA regulatory actions, M&A, licensing, financing, pipeline updates, and executive moves. Stories are ranked by expected market significance and organized into predictable recurring sections — so you always know where to look.
Sources we monitor
We track a curated set of high-signal sources chosen for reliability and time-sensitivity, not volume. Sources include:
How stories are selected
Ingestion
Sources are checked multiple times daily. Articles are collected, deduplicated, and scored for relevance to biotech and life sciences.
Ranking
Stories are ranked by expected market impact — Phase 3 data and FDA approvals outrank earnings beats; major M&A outranks routine filings. Routine governance events (shareholder votes, director elections, proxy amendments) are excluded.
Synthesis
An AI model reads collected articles, writes plain-English summaries, adds “Why it matters” context and a “What to watch” forward-looking note. The model does not make buy/sell recommendations and is explicitly instructed to flag when data has not been disclosed rather than speculate.
Catalyst tracker data labels
The catalyst tracker labels each record by its source and confidence level:
Editor-reviewed catalyst with validated timing, source context, and executive summary. Dates are cross-referenced with company filings, FDA calendars, or press releases.
Pulled from public data sources (ClinicalTrials.gov, SEC EDGAR) and refreshed periodically. Timing and details should be independently verified with company press releases and FDA.gov before acting on them.
Illustrative example only. Not intended for production decision-making. Demo records are hidden by default in production.
Probability of Success (PoS) figures are illustrative benchmark estimates derived from BIO/IQVIA historical phase transition rates (2011–2020). They are not primary research and do not reflect company-specific factors. Always verify with company filings and clinical trial registries.
What “data not yet released” means
When a company announces a topline result without disclosing efficacy or safety figures, we note that “detailed data have not yet been released” rather than speculate. Full numerical results are typically disclosed at a medical conference or in a peer-reviewed publication. Until then, market-moving interpretation should be treated with caution.
Disclaimer
Biotech Brief is for informational purposes only. Nothing published here constitutes investment advice, a solicitation to buy or sell any security, or a recommendation of any particular investment strategy. Data may be incomplete, delayed, or contain errors. Past clinical or regulatory outcomes are not indicative of future results. Always consult qualified financial and medical professionals before making investment or clinical decisions.
Contact & corrections
Spotted an error or have feedback? hello@biotechbrief.news